ProCE Banner Activity

Improving ART Adherence With Point-of-Care Urine Testing: Viewpoints From Africa

Conference Coverage
Clinical Thought

Read my commentary on the use of point-of-care testing to detect TFV concentrations in the urine, including new data presented at CROI 2023 on its use to predict virologic failure in individuals receiving TAF-based ART and incorporation of the urine assay with enhanced adherence counseling as a tool to promote ART adherence among people with HIV with persistent viremia.

Released: March 20, 2023

Expiration: March 18, 2024

No longer available for credit.

Share

Faculty

Sylvia Ojoo

Sylvia Ojoo, CCST (UK), MRCP (UK), DTM&H (UK), DFFP (UK), MBChB

Associate Professor of Medicine
Georgetown University Medical Center
Kisumu, Kenya

Supporters

This activity is supported by an educational grant from

Gilead Sciences, Inc.

Janssen Therapeutics, Division of Janssen Products, LP

Merck & Co., Inc.

ViiV Healthcare

Faculty Disclosure

Primary Author

Sylvia Ojoo, CCST (UK), MRCP (UK), DTM&H (UK), DFFP (UK), MBChB

Associate Professor of Medicine
Georgetown University Medical Center
Kisumu, Kenya

Sylvia Ojoo, CCST (UK), MRCP (UK), DTM&H (UK), DFFP (UK), MBChB, has no relevant financial relationships to disclose.